This study examines the utilisation of opioid substitution therapy among a large community sample of chronic non-cancer pain patients receiving long-term opioid substitution therapy (OST).
The Australian government expends an estimated $1.7 billion on responding to illicit drugs every year, with policing comprising 64% of this expenditure. One core assumption underpinning this investment is that police can deter, discourage or prevent drug offending.
This research project seeks to examine the patterns and costs of Pharmaceutical Benefits Scheme-subsidised opioid use, including extra-medical use, in the Australian population.
We will identify a population cohort of people who use opioids, examine hospitalisations and emergency department visits in this group and determine the impacts of opioid substitution therapy on hospitalisation and emergency department visits.
Drug use can lead to significant financial, psychological, physical health and social consequences for family members. Despite this, previous economic assessments of drug use interventions have not included the costs and benefits to family members of treatment for the drug user.
Opioid agonist treatment is commonly initiated as a first-line treatment for individuals with pharmaceutical opioid dependence, even though much of the evidence base for the use of pharmacotherapy treatments in opioid dependence has been derived from studies conducted with primarily or exclusivel
People who use heroin commonly spend time in prison. Contact with treatment services after release from prison is important for reducing the risk that released heroin users will return to regular drug use.
This study compares the cost-effectiveness of centre-based compulsory rehabilitation (CCT) for substance abuse with community-based methadone maintenance treatment (MMT) in Hai Phong City, Vietnam. The project forms the basis for Thu Vuong's PhD.
The intravenous injection of drugs intended for oral use can cause pulmonary granulamatosis. This project aims to determine the number of cases of sudden or unnatural deaths in which pulmonary granulamatosis was diagnosed, and the medical consequences of pulmonary granulamatosis.